Predicting efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels

Journal of Diabetes Investigation

Volumn 3, Issue 5, 2012, Pages 464-467

  Iwasaki, Masahiro ^a   Hoshian, Fuminori ^a   Tsuji, Tomoko ^a   Hirose, Naoki ^a   Matsumoto, Tomoko ^a   Kitatani, Naomi ^a   Sugawara, Kenji ^a   Usui, Ryota ^a   Kuwata, Hitoshi ^a   Sugizaki, Kazu ^a   Kitamoto, Yuka ^a   Fujiwara, Shuichi ^a   Watanabe, Koin ^a   Hyo, Takanori ^a   Kurose, Takeshi ^a   Seino, Yutaka ^a   Yabe, Daisuke ^a  

^a KANSAI ELECTRIC POWER CO   (Japan)

Author keywords

Dipeptidyl peptidase 4 inhibitor; N 3 Polyunsaturated fatty acid; Type 2 diabetes

Indexed keywords

ALOGLIPTIN; ARACHIDONIC ACID; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DOCOSAHEXAENOIC ACID; HEMOGLOBIN A1C; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; SITAGLIPTIN; VILDAGLIPTIN;

ADULT; ARTICLE; BODY MASS; CLINICAL EXAMINATION; CONTROLLED STUDY; DIABETIC DIET; DRUG EFFICACY; FAT INTAKE; FATTY ACID BLOOD LEVEL; FISH; FOOD INTAKE; HEMOGLOBIN BLOOD LEVEL; HUMAN; JAPANESE; KINESIOTHERAPY; MAJOR CLINICAL STUDY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; SEA FOOD; TREATMENT DURATION;

EID: 84867752550     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2012.00214.x     Document Type: Article

References (11)

1. Dicker D. DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors. Diabetes Care 2011; 34(Suppl 2): S276-S278.
2. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the Two Incretin Hormones: Similarities and Differences. J Diabetes Invest 2010; 1: 9-23.
3. Maeda H, Kubota A, Tanaka Y, et al. The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. Diabetes Res Clin Pract 2012; 95: e20-e22.
4. Monami M, Cremasco F, Lamanna C, et al. Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. Diabetes Metab Res Rev 2011; 27: 362-372.
5. Nomiyama T, Akehi Y, Takenoshita H, et al. Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2012; 95: e27-e28.
6. Seino Y, Nanjo K, Tajima N, et al. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. J Diabetes Invest 2010; 1: 212-228.
7. Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA 2006; 296: 1885-1899.
8. Arterburn LM, Hall EB, Oken H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr 2006; 83: 1467S-1476S.
9. Fedor D, Kelley DS. Prevention of insulin resistance by n-3 polyunsaturated fatty acids. Curr Opin Clin Nutr Metab Care 2009; 12: 138-146.
10. Hirasawa A, Tsumaya K, Awaji T, et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 2005; 11: 90-94.
11. Morishita M, Tanaka T, Shida T, et al. Usefulness of colon targeted DHA and EPA as novel diabetes medications that promote intrinsic GLP-1 secretion. J Control Release 2008; 132: 99-104.